Definitive Contract HHSO100201600008C

This is a $979,538.00 Firm Fixed Price Delivery Order contract awarded to Altimmune, Inc., a for-profit organization, by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The contract, which was not set aside, is for the development of vaccine formulations effective against NIAID priority pathogens, evaluation of clone generation and stability, biodefense vaccine enhancement, and general biomedical research. Altimmune, Inc....

This is a definitive contract awarded by the National Institutes of Health (NIH) to Altimmune, Inc. for $962,248.52 to support the BIODEFENSE VACCINE ENHANCEMENT program. The contract is a Cost Plus Fixed Fee arrangement with an ultimate completion date of August 6, 2013. Altimmune, Inc. is a for-profit organization that specializes in the development of drugs, biologicals, and vaccines, particularly in the area of biodefense. The contract does not have a set-aside designation. Based on the...

This is a $160,848,139.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Cangene Corporation for the development of anthrax therapeutics. The contract has an ultimate completion date of September 30, 2023 and utilizes a combination of pricing types. There is no set-aside designation for this award. The contract is for the research and development of medical countermeasures against anthrax, a critical component of the...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...

This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...

This is a firm fixed-price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to MedImmune LLC for $1,800,000.00. The contract is part of the Pandemic Influenza Preparedness and Response 2016-2021 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle, which is used by ASPR to procure products and services related to pandemic preparedness. The contract has an ultimate completion date of October 31, 2018 and does...

This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...

<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>

This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Sanofi Pasteur Biologics, LLC for the production and testing of a Modified Vaccinia Ankara (MVA) vaccine. The contract award has a ceiling value of $74,940,566.62 and an ultimate completion date of February 6, 2015. The contract is not designated as a set-aside. As a child company of the Sanofi group, Sanofi...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Elusys Therapeutics Inc., a self-certified small disadvantaged business and manufacturer of goods, for the delivery of ANTHIM (obiltoxaximab). The contract has a firm fixed price of $124,650,623.00 and a completion date of April 30, 2027. There is no set-aside designation for this contract. Elusys Therapeutics Inc. is a subsidiary of the...